Page 74 - GALENIKA MEDICAL JOURNAL

16. Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by 31. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity.
cyclosporine. Am J Med. 1987 Jul;83(1):59-64. Clin J Am Soc Nephrol. 2009 Feb;4(2):481-508.
17. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine- 32. Rüster C, Wolf G. Renin-angiotensin-aldosterone system and
associated chronic nephropathy. N Engl J Med. 1984 Sep 13;311(11):699- progression of renal disease. J Am Soc Nephrol. 2006 Nov;17(11):2985-
705. 91.
18. Lewis RM, Janney RP, Van Buren CT, Kerman RH, Herson J, Kerr NA, et al. 33. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et
A retrospective analysis of long-term renal allograft function associated al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors
with cyclosporine-prednisone immunosuppressive therapy. Transplant in renal transplantation. N Engl J Med. 2007 Dec 20;357(25):2562-75.
Proc. 1988 Jun;20(3 Suppl 3):534-9.
34. Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A,
19. M. Colombo, R. Perego and G. Bellia, "Cyclosporine-Associated et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab ®
Nephrotoxicity," Open Journal of Nephrology, Vol. 3 No. 3, 2013, pp. and corticosteroids in renal allograft recipients: the CAESAR Study. Am J
168-180. Transplant. 2007 Mar;7(3):560-70. Sigmasporin
20. Moyer TP, Post GR, Sterioff S, Anderson CF. Cyclosporine nephrotoxicity 35. Matas AJ. Chronic progressive calcineurin nephrotoxicity: an overstated
is minimized by adjusting dosage on the basis of drug concentration in concept. Am J Transplant. 2011 Apr;11(4):687-92.
blood. Mayo Clin Proc. 1988 Mar;63(3):241-7.
36. Burke JF Jr, Pirsch JD, Ramos EL, Salomon DR, Stablein DM, Van Buren
21. Holt DW, Marsden JT, Johnston A, Bewick M, Taube DH. Blood DH, et al. Long-term efficacy and safety of cyclosporine in renal-
cyclosporin concentrations and renal allograft dysfunction. Br Med J transplant recipients. N Engl J Med. 1994 Aug 11;331(6):358-63. ciklosporin
(Clin Res Ed). 1986 Oct 25;293(6554):1057-9.
37. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, et al.
22. Flores C, Fouquet G, Moura IC, Maciel TT, Hermine O. Lessons to Learn Evidence for antibody-mediated injury as a major determinant of late
From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical kidney allograft failure. Transplantation. 2010 Jul 15;90(1):68-74.
Applications. Front Immunol. 2019 Mar 28;10:588.
38. Shah SR, Altaf A, Arshad MH, Mari A, Noorani S, Saeed E, et al. Use of
23. Kahan BD. Cyclosporine. N Engl J Med. 1989 Dec 21;321(25):1725-38. Cyclosporine Therapy in Steroid Resistant Nephrotic Syndrome (SRNS):
A Review. Glob J Health Sci. 2015 Aug 6;8(4):136-41.
24. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring
of immunosuppressant drugs in clinical practice. Clin Ther. 2002 39. Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis:
Mar;24(3):330-50; discussion 329. assessing the evidence. Nephrol Dial Transplant. 2009 Jan;24(1):15-20.
25. Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, et al. 40. Ponticelli C, Podestà MA. Calcineurin inhibitors in lupus nephritis. J
Cyclosporin A initially as the only immunosuppressant in 34 recipients Nephrol. 2021 Apr;34(2):399-402.
of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet.
1979 Nov 17;2(8151):1033-6. 41. Weissman S, Chris-Olaiya A, Mehta TI, Aziz M, Alshati A, Berry R, et al. A
novel player: cyclosporine therapy in the management of inflammatory
26. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration bowel disease. Transl Gastroenterol Hepatol. 2019 Sep 10;4:67.
on renal hemodynamics in conscious rats. Kidney Int. 1985
Nov;28(5):767-74. 42. Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB. National Psoriasis
Foundation. Cyclosporine and psoriasis: 2008 National Psoriasis
27. Hortelano S, Castilla M, Torres AM, Tejedor A, Boscá L. Potentiation Foundation Consensus Conference. J Am Acad Dermatol. 2010
by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal May;62(5):838-53.
proximal tubule cells. J Am Soc Nephrol. 2000 Dec;11(12):2315-23.
28. Höcherl K, Dreher F, Vitzthum H, Köhler J, Kurtz A. Cyclosporine A
suppresses cyclooxygenase-2 expression in the rat kidney. J Am Soc Konflikt interesa: Nema
Nephrol. 2002 Oct;13(10):2427-36.
Primljeno: 16. 10. 2023.
29. Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E, Prihvaćeno: 06. 11. 2023.
Luetscher JA, Whitney DJ, Krasny D, Coplon NS, et al. The long-term
course of cyclosporine-associated chronic nephropathy. Kidney Int. Onlajn: 01. 12. 2023.
1988 Feb;33(2):590-600.
30. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, Jouanneau C, Jaudon
MC, Maksud P, et al. Long-term renal effects of low-dose cyclosporine
in uveitis-treated patients: follow-up study. J Am Soc Nephrol. 2002
Dec;13(12):2962-8.

Samo za
72 DOI: 10.5937/Galmed2308067N stručnu javnost.